Dr. Williams was most recently the CEO and Board Chairman of Five Prime Therapeutics, a company he founded in 2001. To pursue innovative startup company activities, he stepped down as Five prime CEO in 2017 and as Chairman in December, 2018. He continues to serve on the Board of Directors and is Head of the Scientific Advisory Board. He led Five Prime in the development of its platform, through the initiation and execution of multiple clinical trials, during its successful IPO and subsequent public offerings, and in numerous high-value partnering transactions. In the past Dr Williams was a co-founder of Cor Therapeutics, a cardiovascular biotherapeutics company which was acquired by Millennium Pharmaceuticals for $2 B. He served on the Cor Board through its IPO and early clinical trials. He also spent seven years at Chiron Corporation, a biopharmaceutical company (now Novartis Vaccines and Diagnostics, Inc), and served as its Chief Scientific Officer and was a member of its Board of Directors. Dr. Williams is currently on the board of Protagonist Therapeutics and he was previously on the Board of the Beckman Coulter Corporation, until it was acquired by Danaher. Earlier in his career Dr. Williams was a professor of medicine and cardiology at the University of California, San Francisco and served as director of the University’s Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. He also served as an Investigator of the Howard Hughes Medical Institute from 1985 through 1993. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University. He has served on the Boards of Duke, Rice and the Berklee College of Music.